According to the American Health announcement, Yu Rong, the actual controllers of the company, Tongyi Taoli No. 3 and Tongyi Taoli No. 12 private equity investment funds intend to reduce their holdings by no more than 206.66 million shares in total through centralized bidding within 3 months after 15 trading days from the date of publication of the pre-disclosure notice, accounting for 0.53% of the company's total share capital. Among them, Tongyi No. 3 plans to reduce its holdings by no more than 14.069,500 shares, accounting for 0.36% of the total share capital; Tongyi No. 12 plans to reduce its holdings by no more than 6.5966 million shares, accounting for 0.17% of the total share capital. The reason for this reduction in holdings is due to its own capital requirements, which will not lead to a change in the company's control and will not affect the company's continued operation.

According to the American Health announcement, Yu Rong, the actual controllers of the company, Tongyi Taoli No. 3 and Tongyi Taoli No. 12 private equity investment funds intend to reduce their holdings by no more than 206.66 million shares in total through centralized bidding within 3 months after 15 trading days from the date of publication of the pre-disclosure notice, accounting for 0.53% of the company's total share capital. Among them, Tongyi No. 3 plans to reduce its holdings by no more than 14.069,500 shares, accounting for 0.36% of the total share capital; Tongyi No. 12 plans to reduce its holdings by no more than 6.5966 million shares, accounting for 0.17% of the total share capital. The reason for this reduction in holdings is due to its own capital requirements, which will not lead to a change in the company's control and will not affect the company's continued operation.